Neurome Inc has entered into a research agreement with Wyeth, in which Neurome will employ its proprietary technologies and expertise in quantitative neuropathology to assist Wyeth in its Discovery Research efforts involving treatment of Central Nervous System (CNS) disorders. Under the terms of the multi-year agreement, Neurome will receive research funding from Wyeth.

In this collaboration, Neurome and Wyeth will work together to investigate a number of aspects of CNS disease, beginning with the comprehensive evaluation and morphological analysis of one of Wyeth's transgenic animal models of Alzheimer's disease used to evaluate selected preclinical compounds. The collaboration will leverage Neurome's extensive experience with animal models of CNS diseases and proprietary technologies (the Neurome Technologies) to derive quantitative 3-D information, including volumetric analysis, on these animals.